Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 6/20 | 0.64 |
| ▸ | MME | P08473 | 1/20 | 0.59 |
| ▸ | ECE1 | P42892 | 1/20 | 0.59 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 2/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9698236 | 1.00 | FOLH1 (0.64) | FOLH1MMEECE1NAALAD2PPARA | |
| SCHEMBL24238520 | 1.00 | FOLH1 (0.64) | FOLH1MMEECE1NAALAD2PPARA | |
| SCHEMBL19307785 | 1.00 | FOLH1 (0.64) | FOLH1MMEECE1NAALAD2PPARA | |
| SCHEMBL9697060 | 1.00 | FOLH1 (0.64) | FOLH1MMEECE1NAALAD2PPARA | |
| SCHEMBL9955269 | 0.96 | FOLH1 (0.60) | FOLH1MMEECE1NAALAD2PPARA | |
| SCHEMBL9955274 | 0.96 | FOLH1 (0.60) | FOLH1MMEECE1NAALAD2PPARA | |
| SCHEMBL910423 | 0.95 | FOLH1 (0.70) | FOLH1MMEECE1NAALAD2PPARA | |
| SCHEMBL910233 | 0.95 | FOLH1 (0.70) | FOLH1MMEECE1NAALAD2PPARA | |
| SCHEMBL910232 | 0.95 | FOLH1 (0.70) | FOLH1MMEECE1NAALAD2PPARA | |
| Benzene SCHEMBL28226069 | 0.95 | FOLH1 (0.70) | FOLH1MMEECE1NAALAD2PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033817-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-02-03 | — | — | US | disclosed |
| CN-113797348-A | Targeting ligands for therapeutic compounds | 箭头药业股份有限公司 | 2021-12-17 | — | — | CN | disclosed |
| US-11174481-B2 | Targeting ligands | Arrowhead Pharmaceuticals, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11174481-B2 | Targeting ligands | Arrowhead Pharmaceuticals, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| CN-109069529-B | Targeting ligands for therapeutic compounds | 箭头药业股份有限公司 | 2021-08-20 | — | — | CN | disclosed |
| US-20210189394-A1 | Targeting Ligands For Therapeutic Compounds | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2021-06-24 | — | — | US | disclosed |
| US-20190256849-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-08-22 | — | — | US | disclosed |
| US-20190256849-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-08-22 | — | — | US | disclosed |
| EP-3506913-A1 | TARGETING LIGANDS | Arrowhead Pharmaceuticals, Inc. (US) | 2019-07-10 | — | — | EP | disclosed |
| WO-2018044350-A1 | TARGETING LIGANDS | ARROWHEAD PHARMACEUTICALS, INC (US) | 2018-03-08 | — | — | WO | disclosed |
| WO-2018044350-A1 | TARGETING LIGANDS | ARROWHEAD PHARMACEUTICALS, INC (US) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033817-A1 | Targeting Ligands | FABP1, SNRPE, HAVCR2 | FOLH1 1153/4885MME 2748/4885ECE1 2585/4885 |
| US-20190256849-A1 | Targeting Ligands | FABP1, SNRPE, HAVCR2 | FOLH1 1153/4885MME 2748/4885ECE1 2585/4885 |
| US-20210189394-A1 | Targeting Ligands For Therapeutic Compounds | FABP1, SNRPE, HAVCR2 | FOLH1 1083/4885MME 2770/4885ECE1 2869/4885 |
| US-11174481-B2 | Targeting ligands | FABP1, SNRPE, HAVCR2 | FOLH1 1153/4885MME 2748/4885ECE1 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.